Featured Research

from universities, journals, and other organizations

Traitorous immune cells promote sudden ovarian cancer progression

Date:
February 20, 2012
Source:
The Wistar Institute
Summary:
In a new mouse model that mimics the tumor microenvironment of ovarian cancer, scientists have demonstrated that ovarian tumors don't necessarily break "free" of the immune system, rather dendritic cells of the immune system seem to actively support the tumor's escape. The researchers show that it might be possible to restore the immune system by targeting a patient's own dendritic cells.

Cell studies show physical differences among dendritic cells in ovarian tumors that have progressed, highlighting the link between these cells and the ability of tumors to evade the immune system.
Credit: Image courtesy of The Wistar Institute

Aggressive ovarian tumors begin as malignant cells kept in check by the immune system until, suddenly and unpredictably, they explode into metastatic cancer. New findings from scientists at The Wistar Institute demonstrate that ovarian tumors don't necessarily break "free" of the immune system, rather dendritic cells of the immune system seem to actively support the tumor's escape. The researchers show that it might be possible to restore the immune system by targeting a patient's own dendritic cells.

Related Articles


"Our model shows where the cancer is kept in check for relatively long periods, but once they become noticeable, tumors grow exponentially," said Josι R. Conejo-Garcia, M.D., Ph.D., an associate professor at Wistar and leader of the Tumor Microenvironment and Metastasis Program of Wistar's Cancer Center. "More importantly, we show that by depleting these dendritic cells of the immune system, we can reverse the effect, once again allowing our immune system to recognize the ovarian tumors."

Their findings, presented in the March issue of the Journal of Experimental Medicine, available online now, represent the first successful attempt to model the tumor microenvironment of human ovarian cancer in a mouse model of the disease. In essence, the model replicates the inflammatory surroundings that ovarian tumors experience in humans. The more accurate model provides a better tool for researchers to understand, prevent, and treat tumors.

"Our system uses oncogene-driven tumors that are spontaneously antigenic, thus avoiding the use of artificial foreign antigens that do not accurately replicate what drives anti-tumor immune responses in humans," Conejo-Garcia said.

Ovarian cancer remains one of the most deadly forms of cancer in women. According to the National Cancer Institute, 21,990 women will be diagnosed with ovarian cancer, and 15,460 women will die of the disease this year. Because early-stage ovarian cancer does not often exhibit noticeable symptoms, many women are not diagnosed until the cancer is at a later stage, when it is most difficult to treat.

"While we have seen an increase in survival rates for most cancers over the last 40 years, ovarian cancer survival has only improved slightly since the 1970s," Conejo-Garcia said. "We created our ovarian cancer model to get a better understanding of how these tumors acquire such aggressive characteristics and evade the immune system."

According to Conejo-Garcia, their model demonstrates how a localized ovarian tumor flares into an aggressive metastatic disease.

"You can see where, if one ovary is cancerous, it is almost unrecognizable until an instantaneous moment, when it explodes into exponential growth," Conejo-Garcia said. "The key to this moment, our evidence suggests, is in the phenotypic changes taking place in the dendritic cells that are part of the tumor microenvironment."

In healthy tissue, dendritic cells function as sort of alarm system to alert the adaptive part of the immune system to potential threats. They work as antigen-presenting cells, offering foreign or disease-causing molecules (called antigen) to the white blood cells that can then respond to an infection or, in this case, tumorous growths. Amid the ovarian cancer microenvironment, dendritic cells also induce the immune system to attack tumor cells and inhibit their growth.

Until, that is, dendritic cells seem to switch sides.

"We see a change in the dendritic cells themselves, which allows tumors to progress to terminal disease in a very short time," Conejo-Garcia said. "Interestingly, the tumors themselves are still immunogenic -- they could still otherwise elicit an immune response -- it is just that the dendritic cells are actively suppressing the involvement of other anti-tumor immune cells; primarily T cells."

Conejo-Garcia and his colleagues believe that their findings offer a twist on the emerging theory of "cancer immunoediting." The immunoediting hypothesis suggests that the immune system actively "edits" tumor cells to eliminate antigens that are recognized by immune cells, keeping the cancer at bay before it becomes symptomatic. All symptomatic tumors, therefore, represent a failure of the immune system, where tumors lose their immunogenicity -- their ability to trigger and be recognized by our immune system.

The researchers found that depleting dendritic cells early on accelerating tumor expansion, while removing dendritic cells later on actually delayed the tumor's progression. According to Conejo-Garcia, their findings suggest it is a change in the immune system itself, specifically the dendritic cells, and not primarily any loss of immunogenicity on the part of the tumor.

"It is almost as if anti-tumor T cells become exhausted, they can no longer keep up the effort," Conejo-Garcia said. "Still, our findings suggest that the enduring activity of these T cells would allow us to control metastatic ovarian cancer by targeting the dendritic cells that actively prevent their anti-tumor functions."

In fact, Conejo-Garcia and his colleagues have already developed a strategy to reprogram traitorous dendritic cells. In a an upcoming edition of the journal Cancer Research, available online now, the researchers demonstrate how synthetic RNA molecules can be used to win back the allegiance of dendritic cells and restore their ability to stimulate tumor suppression.

Funding for this research was provided through grants from the National Cancer Institute and the Department of Defense.

The lead author of the study is Uciane K. Scarlett, Ph.D., a staff scientist in the Conejo-Garcia laboratory. Wistar co-authors also include Melanie R. Rutkowski, Ph.D. and Ximena Escovar-Fadul. Co-authors from Darmouth Medical School include Adam M. Rauwerdink, Ph.D., Jennifer Fields, Jason Baird, Juan R. Cubillos-Ruiz, Ph.D. (currently at Harvard University), Ana C. Jacobs, Jorge L. Gonzalez, M.D., John Weaver, Ph.D., and Steven Fiering, Ph.D.


Story Source:

The above story is based on materials provided by The Wistar Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Uciane K. Scarlett, Melanie R. Rutkowski, Adam M. Rauwerdink, Jennifer Fields, Ximena Escovar-Fadul, Jason Baird, Juan R. Cubillos-Ruiz, Ana C. Jacobs, Jorge L. Gonzalez, John Weaver, Steven Fiering, and Jose R. Conejo-Garcia. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. Journal of Experimental Medicine, 2012 DOI: 10.1084/jem.20111413

Cite This Page:

The Wistar Institute. "Traitorous immune cells promote sudden ovarian cancer progression." ScienceDaily. ScienceDaily, 20 February 2012. <www.sciencedaily.com/releases/2012/02/120220102144.htm>.
The Wistar Institute. (2012, February 20). Traitorous immune cells promote sudden ovarian cancer progression. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2012/02/120220102144.htm
The Wistar Institute. "Traitorous immune cells promote sudden ovarian cancer progression." ScienceDaily. www.sciencedaily.com/releases/2012/02/120220102144.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins